DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

Oncolytic Immunotherapy for Diffuse Intrinsic Pontine Gliomas

Principal Investigator: GOMEZ-MANZANO, CANDELARIA
Institution Receiving Award: M.D. ANDERSON CANCER CENTER, UNIVERSITY OF TEXAS
Program: PRCRP
Proposal Number: CA160525P1
Award Number: W81XWH-17-1-0311
Funding Mechanism: Translational Team Science Award
Partnering Awards: CA160525, CA160525P2
Award Amount: $341,855.00


PUBLIC ABSTRACT

Diffuse intrinsic pontine glioma (DIPG) is one of the most formidable challenges faced by pediatric oncologist. For the last 30 years, all treatment approaches for these types of tumors have failed, leaving a terrible prospect of survival at 5 years for these children virtually of zero. Thus, it is clear that new therapeutic strategies are required that allow not only for more effective treatments of these tumors but also that defer the severe side effects derived from the current therapeutic choices. Oncolytic adenoviruses designed to replicate in and destroy tumor cells selectively represent a promising new therapeutic strategy that could improve the outcome of this malignancy. Delta-24-RGD is a tumor selective oncolytic virus that has been being tested in a Phase I clinical trial in adults with brain tumors with very promising results. The virus showed lack of toxicity and some degree of efficacy due to the trigger of an immune response against the tumor. Therefore, strategies directed to boost the immune response would be amenable to use in combination with the virus. In this project, we propose to combine Delta-24-RGD with different approaches that will result in an effective antitumor effect without compromising safety for DIPGs.

We believe these viruses will be able to awaken the own immune system and therefore to destroy the tumors. Altogether, we hope this strategy will demonstrate safety and efficacy for these terrible tumors, bringing hope not only to military families but to any family dealing with DIPGs. If successful, at the end of the 3 years of this project, we will be in the position to propel a clinical trial Phase I/II for children with DIPGs with one of the innovative therapeutic strategies developed and tested during the course of this project.